PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: Pembrolizumab|DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Olaparib|DRUG: Capecitabine
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins